A prospective long-term study was conducted to evaluate the prophylactic effect and safety of propranolol in upper gastrointestinal bleeding for 46 patients with portal hypertension untreated by sclerotherapy. The duration of administration at the maintenance dose, which was to decrease the resting heart rate by 25%, was 33.5±19.6 weeks. Of the 45 patients, 3 patients experienced bleeding from upper gastrointestinal tract and cumulative non-bleeding ratio was 90.9%. Significant improvement was observed in the form and red color sign of the varices compared with the baseline by endoscopy. A total of 8 adverse events were reported in 5 of 46 patients evaluable for safety. Of them, 4 patients were withdrawn from the study due to the events, however, there was no clinically problematic cases. Propranolol was considered as a useful drug in prevention of upper gastrointestinal bleeding for the patients with portal hypertension, in terms of the efficacy and safety.
All Science Journal Classification (ASJC) codes